Anish Thomas - Concepedia

Author

Anish Thomas

Also Known As

A Thomas, A. Thomas, A.P. Thomas, ALEN THOMAS, ANISH THOMAS, Abraham I Thomas, Ajibola A. Thomas, Anish Thomas, Anish Thomas, Anish. Thomas

564

Publications

13.4K

Citations

H-Index

104

Concepts

All Affiliations

National Cancer Institute Center for Cancer Research National Institutes of Health Georgetown University National Institutes of Health Clinical Center

About

Anish Thomas is an author at National Cancer Institute specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	23	43	5.6K
2	Health Sciences	5	5	560
3	Engineering	3	3	350
4	Natural Sciences	2	2	46
5	Nursing	1	1	14

Anish Thomas

Publications

9.6K

Citations

H-Index

Page 1

	Year	Citations
Cancer Statistics, 2002 Ahmedin Jemal, Anish Thomas, Thomas S. Murray, CA A Cancer Journal for Clinicians American Cancer SocietyCancer StatisticsEpidemiologyCancer EpidemiologyMedicine	2002	2.9K
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline Hedy L. Kindler, Nofisat Ismaila, Samuel G. Armato, Journal of Clinical Oncology Surgical OncologyCancer ManagementMultimodalityAmerican SocietyPleural Effusion	2018	403
Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial Anish Thomas, Arun Rajan, Arlene Berman, The Lancet Oncology Open-label Phase 2OncologyClinical TrialsImmune Checkpoint InhibitorDermatology	2015	293
Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression Raffit Hassan, Andrew C. Miller, Elad Sharon, Science Translational Medicine	2013	237
Molecular Profiling and Targeted Therapy for Advanced Thoracic Malignancies: A Biomarker-Derived, Multiarm, Multihistology Phase II Basket Trial Ariel López-Chávez, Anish Thomas, Arun Rajan, Journal of Clinical Oncology	2015	234
Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma Raffit Hassan, Hedy L. Kindler, Thierry Jahan, Clinical Cancer Research	2014	182
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study Anish Thomas, Rasa Vilimas, Christopher Trindade, Journal of Thoracic Oncology Clinical TherapeuticMedicineMetronomic TherapyPharmacologyClinical Trials	2019	178
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress Anish Thomas, Nobuyuki Takahashi, Vinodh N. Rajapakse, Cancer Cell OncologyEngineeringHigh Replication StressMedicineOncogenic Agent	2021	172
A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer Ronan J. Kelly, Anish Thomas, Arun Rajan, Annals of Oncology Phase I/ii StudyMedicinePharmacologyBronchial NeoplasmSurvivin Suppressor	2013	171
Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front‐line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125 Raffit Hassan, Elad Sharon, Anish Thomas, Cancer	2014	168

Page 1